Barinthus Biotherapeutics plc
BRNS
$1.20
$0.0151.27%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | 14.97M | 14.97M | 14.97M | 14.97M | 0.00 |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 14.97M | 14.97M | 14.97M | 14.97M | 0.00 |
Cost of Revenue | 8.42M | 8.92M | 11.70M | 12.25M | 11.11M |
Gross Profit | 6.55M | 6.05M | 3.27M | 2.72M | -11.11M |
SG&A Expenses | 38.79M | 30.60M | 24.01M | 41.02M | 28.42M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -436.00K | -1.00M | -976.00K | -792.00K | -582.00K |
Total Operating Expenses | 69.37M | 64.98M | 60.90M | 77.70M | 68.72M |
Operating Income | -54.40M | -50.01M | -45.93M | -62.73M | -68.72M |
Income Before Tax | -69.55M | -65.35M | -61.23M | -58.75M | -65.33M |
Income Tax Expenses | -47.00K | -29.00K | -44.00K | -867.00K | -1.47M |
Earnings from Continuing Operations | -69.50 | -65.32 | -61.18 | -57.88 | -63.86 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | 78.00K | 88.00K | 109.00K | 55.00K | 78.00K |
Net Income | -69.43M | -65.23M | -61.07M | -57.83M | -63.79M |
EBIT | -54.40M | -50.01M | -45.93M | -62.73M | -68.72M |
EBITDA | -50.66M | -46.80M | -43.33M | -60.12M | -66.12M |
EPS Basic | -1.73 | -1.64 | -1.55 | -1.49 | -1.65 |
Normalized Basic EPS | -0.80 | -0.74 | -0.69 | -0.95 | -1.06 |
EPS Diluted | -1.74 | -1.65 | -1.56 | -1.49 | -1.65 |
Normalized Diluted EPS | -0.80 | -0.74 | -0.69 | -0.95 | -1.06 |
Average Basic Shares Outstanding | 160.18M | 158.88M | 157.39M | 155.82M | 154.93M |
Average Diluted Shares Outstanding | 160.18M | 158.88M | 157.39M | 155.82M | 154.93M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |